Detalles de la búsqueda
1.
Global real-world experiences with pembrolizumab in advanced urothelial carcinoma after platinum-based chemotherapy: the ARON-2 study.
Cancer Immunol Immunother
; 73(6): 106, 2024 Apr 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-38634928
2.
Genomic Profiling and Molecular Characterisation of Metastatic Urothelial Carcinoma.
Medicina (Kaunas)
; 60(4)2024 Mar 31.
Artículo
en Inglés
| MEDLINE | ID: mdl-38674231
3.
Real-world effectiveness of pembrolizumab as first-line therapy for cisplatin-ineligible patients with advanced urothelial carcinoma: the ARON-2 study.
Cancer Immunol Immunother
; 72(9): 2961-2970, 2023 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-37248424
4.
Use of concomitant proton pump inhibitors, statins or metformin in patients treated with pembrolizumab for metastatic urothelial carcinoma: data from the ARON-2 retrospective study.
Cancer Immunol Immunother
; 72(11): 3665-3682, 2023 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-37676282
5.
SIRM-SIN-AIOM: appropriateness criteria for evaluation and prevention of renal damage in the patient undergoing contrast medium examinations-consensus statements from Italian College of Radiology (SIRM), Italian College of Nephrology (SIN) and Italian Association of Medical Oncology (AIOM).
Radiol Med
; 127(5): 534-542, 2022 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-35303246
6.
A multiparametric approach to improve the prediction of response to immunotherapy in patients with metastatic NSCLC.
Cancer Immunol Immunother
; 70(6): 1667-1678, 2021 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-33315149
7.
The heterogeneity of cancer endothelium: The relevance of angiogenesis and endothelial progenitor cells in cancer microenvironment.
Microvasc Res
; 138: 104189, 2021 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-34062191
8.
Safety and Efficacy of Tivozanib in First-Line mRCC: A Multicenter Compassionate-Use Study (Meet-Uro 16).
Oncology
; 99(12): 747-755, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-34583356
9.
Individualizing renal cell carcinoma treatment through biomarkers discovery in the era of immune checkpoint inhibitors: where do we stand?
Curr Opin Urol
; 31(3): 236-241, 2021 05 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-33742982
10.
Treatment-related fatigue with sorafenib, sunitinib and pazopanib in patients with advanced solid tumors: an up-to-date review and meta-analysis of clinical trials.
Int J Cancer
; 136(1): 1-10, 2015 Jan 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-24415642
11.
Sunitinib, pazopanib or sorafenib for the treatment of patients with late relapsing metastatic renal cell carcinoma.
J Urol
; 193(1): 41-7, 2015 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-25046616
12.
Surgical resection does not improve survival in patients with renal metastases to the pancreas in the era of tyrosine kinase inhibitors.
Ann Surg Oncol
; 22(6): 2094-100, 2015.
Artículo
en Inglés
| MEDLINE | ID: mdl-25472645
13.
Everolimus as second-line therapy for metastatic renal cell carcinoma: a 'real-life' study.
Future Oncol
; 11(2): 219-24, 2015.
Artículo
en Inglés
| MEDLINE | ID: mdl-25078333
14.
Sorafenib as first- or second-line therapy in patients with metastatic renal cell carcinoma in a community setting.
Future Oncol
; 10(10): 1741-50, 2014 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-24641206
15.
Assessing the effectiveness and safety of lenvatinib and everolimus in advanced renal cell carcinoma: insights from the RELIEVE study's analysis of heavily pretreated patients.
Ther Adv Urol
; 16: 17562872241244574, 2024.
Artículo
en Inglés
| MEDLINE | ID: mdl-38638242
16.
Neutrophil-to-Eosinophil Ratio Predicts the Efficacy of Avelumab in Patients With Advanced Urothelial Carcinoma Enrolled in the MALVA Study (Meet-URO 25).
Clin Genitourin Cancer
; 22(4): 102099, 2024 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-38776583
17.
Real-world Outcome of Patients with Advanced Renal Cell Carcinoma and Intermediate- or Poor-risk International Metastatic Renal Cell Carcinoma Database Consortium Criteria Treated by Immune-oncology Combinations: Differential Effectiveness by Risk Group?
Eur Urol Oncol
; 7(1): 102-111, 2024 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-37481365
18.
Genomic Profiling and Molecular Characterization of Clear Cell Renal Cell Carcinoma.
Curr Oncol
; 30(10): 9276-9290, 2023 10 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-37887570
19.
Artificial intelligence-based prediction of overall survival in metastatic renal cell carcinoma.
Front Oncol
; 13: 1021684, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-36874081
20.
Immune checkpoint inhibitors in non-conventional histologies of renal-cell carcinoma.
Hum Vaccin Immunother
; 19(1): 2171672, 2023 12 31.
Artículo
en Inglés
| MEDLINE | ID: mdl-36758960